Update shared on 25 Nov 2025
Analysts have adjusted their price target for Bonesupport Holding, maintaining it at SEK 391.20. Recent evaluations indicate steady expectations in light of updated discount rates and continued confidence in the company's growth and profitability outlook.
What's in the News
- Bonesupport announced positive results from a clinical study of CERAMENT G, showing significantly improved patient-reported outcomes for single-stage revision surgery in patients with hip periprosthetic joint infection (PJI) (Key Developments).
- The study involved twenty patients at Charite, Universitatsmedizin Berlin, with none experiencing re-infection during a 24-month follow-up (Key Developments).
- Data showed significant improvements in the Harris Hip Score, EQ-5D-5L, and Pain Visual Analogue Scale compared to traditional two-stage procedures (Key Developments).
- The findings were presented at the European Bone and Joint Infection Society annual meeting and the study (CeraHip) is expected to be published in the autumn (Key Developments).
- Current standard of care involves a two-stage procedure, with a 30% risk of reinfection within two years according to the German Arthroplasty Registry (Key Developments).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at SEK 391.20.
- Discount Rate has increased slightly from 5.08% to 5.13%.
- Revenue Growth forecast is steady at 38.42%.
- Net Profit Margin projection remains stable at 30.88%.
- Future P/E ratio has declined slightly from 32.68x to 32.23x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.